News

Chiesi has entered into a definitive agreement to acquire Kalvista Pharmaceuticals, and with it, Ekterly (sebetralstat), an oral on‑demand treatment for acute swelling attacks in people with hereditary angioedema (HAE). The transaction was approved by both companies’ boards of directors and is expected to be completed by the…

A single dose of lonvoguran ziclumeran (lonvo-z) left more than 60% of patients with hereditary angioedema (HAE) free of swelling attacks and ongoing therapy during a six-month evaluation period, suggesting it could reduce the need for lifelong preventive therapy if approved. That is according to topline data from…

Advocates around the world are preparing to mark May 16 as the day of awareness for hereditary angioedema (HAE), a rare genetic disorder that still takes an average of eight years to diagnose. Since its inception in 2012, the annual observance known as “hae day :-)” has evolved…

On May 16, organizations and supporters worldwide will mark hae day : -) — designed to raise awareness of hereditary angioedema (HAE) — through a range of activities, from a foot race around the bridges of Osijek, Croatia, to the illumination of landmarks throughout Canada. The annual event…

Using a daily extended-release tablet of deucrictibant — an oral small molecule being developed by Pharvaris — together with deucrictibant in its immediate-release formulation as an on-demand treatment for acute attacks of hereditary angioedema (HAE) is expected to be safe based on computer data. A presentation on…

The experimental therapy navenibart was well tolerated and was associated with fewer swelling attacks and improved quality of life in adults with hereditary angioedema (HAE) when given every few months in an early clinical trial, a study showed. “The proof-of-concept data … suggest that infrequent administration of navenibart…

It wasn’t until nearly a decade after she first started experiencing symptoms that a woman in China was diagnosed with hereditary angioedema (HAE), despite a family history of swelling bouts and years of abdominal pain, as described in a new report. A routine blood test at age…

Treatment with Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), was associated with strong symptom control in people with mast cell–mediated angioedema, according to a large real-world study. Benefits were observed regardless of whether patients experienced wheals, itchy skin bumps commonly known as…

On-demand treatment with Ekterly (sebetralstat), marketed by Kalvista Pharmaceuticals for hereditary angioedema (HAE), reduced anxiety associated with swelling attacks more quickly and effectively than a placebo in a recent study. “Moderate-to-extreme anxiety was common,” the researchers wrote, but it eased with treatment, particularly in patients who were…

Deucrictibant, an experimental oral small molecule from Pharvaris, delivers rapid relief when used on demand for acute attacks of hereditary angioedema (HAE) and can, over time, also reduce the frequency of the swelling that causes the attacks,…